Inhibikase Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$2(as of Dec 26, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Inhibikase Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$2
Ticker SymbolIKT
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees15
CountyUSA
Market Cap$119.2M

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Inhibikase Therapeutics Inc In Our Stock Scanner

As of Dec 29, 2025
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.